ArticleInternational journal of ophthalmology2026
Effect of intravitreal injection of dexamethasone implant on the corneal morphology of young adults with central retinal vein occlusion.
Article in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the effect of intravitreal injection of dexamethasone (DEX) implants on the corneal morphology of young adults with central retinal vein occlusion (CRVO).
methodsThis was a retrospective study. The information of all patients was collected from the hospital information system. Patients diagnosed with CRVO were included. Corneal morphometric analysis was performed 1, 3, 6, and 12mo after the intravitreal injection of DEX. Corneal endothelial cell density (ECD), hexagonal cell ratio (HEX), and coefficient of variation (CV), central corneal thickness (CCT), anterior chamber depth (ACD), anterior chamber angle (ACA), and anterior chamber volume (ACV) were evaluated.
resultsThe mean age of the 80 patients (80 eyes) with CRVO was 33.10±3.26y. The mean disease duration was 4.94±2.12mo. The ECDs before and 1, 3, 6, and 12mo after DEX injection were 2718.22±333.14, 2692.74±324.84, 2577.55±365.27, 2624.30±345.53 cells/mm², and 2604.00±321.19 cells/mm², respectively. No difference was found in ECD at 1, 6, and 12mo after the injection compared with baselines. The ECD of patients was lower than baseline at three months (
conclusionIn young adults with CRVO, intravitreal injection of DEX can temporarily decrease ECD. However, the remaining corneal endothelial morphological characteristics and anterior chamber parameters are unaffected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.